Working independently, each writing committee sur- veyed the evidence, arrived at similar conclusions, and constructed similar, but not identical, recommendations. Given the concordance, the respective organizations si- multaneously issued aligned recommendations on the use of these new treatments to minimize confusion and improve the care of patients with HF. Members of the ACC/AHA/HFSA writing committee without relevant RWI voted on the final recommendations. These were subjected to external peer review by 25 official, organizational, and content reviewers before ap- proval by the Task Force and the leadership of the ACC, AHA, and HFSA, as well as endorsement by the American College of Chest Physicians and the International Society for Heart and Lung Transplantation. The statements is- sued by the European Society of Cardiology writing com- mittee went through a similarly rigorous process of exter- nal review before endorsement by the societal leadership. No single clinical trial answers all pertinent questions, nor can trial results be perfectly replicated in clinical practice. Several critical questions remain unanswered, and further experience in both ongoing trials and clinical therapeutics may require modification of these initial rec- ommendations. On the basis of the currently available evidence, however, the recommendations that follow reflect our assessment of how best to proceed today. 7.3. Stage C 7.3.2. Pharmacological Treatment for Stage C HF With Reduced Ejection Fraction: Recommendations 7.3.2.10. Renin-Angiotensin System Inhibition With Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker or ARNI: Recommendations See the Online Data Supplement for evidence supporting these recommendations. 